跳至主要内容

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

 On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs.

Medicilon and Binhui Biopharmaceutical have reached a strategic collaboration to jointly draw a new blueprint for the development of new biological drugs.webp

Gather and Work Together to Create Advantages
     Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs

As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs, mRNA vaccines, small nucleic acid drugs, PROTAC, and CGT technical service platform that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation for establishing deeper and broader collaborative relationships with global partners.

Binhui Bio has the only fully closed-loop industry-university-research integrated research platform in China for the development of oncolytic virus products - the oncolytic virus (oHSV2) immunotherapy platform.  It collaborates with multiple technology platforms of nucleic acid drugs and protein drugs to develop new Class I biological drugs, and become a pioneer in the collaborative exploration of multi-platform technologies for tumor immunotherapy.  The company's core oncolytic virus product BS001 (OH2 injection) has received NMPA and FDA approval for a total of 5 clinical approvals as a single drug and combination drug, becoming the first in the world to enter clinical research using type Ⅱ herpes simplex virus as a vector and obtain positive efficacy data of oncolytic viruses.  It is also the first major national new drug creation project for oncolytic viruses to enter confirmatory phase III clinical research.

This powerful alliance between the two parties benefits from Medicilon's drug research and development service capabilities accumulated over the years, as well as Binhui Bio's successful experience in the field of new biological drug research and development.  Based on the common vision and goals, both parties will give full play to their respective advantages in technology R&D and market expansion to achieve complementary advantages, effectively utilize resources, expand the market business scale of both parties, and create a professional contract R&D service platform.  Both parties jointly promote the research, development and application of cutting-edge technologies such as oncolytic viruses, nucleic acid drugs and protein drugs.

标签：

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati
发表评论
阅读全文